#United States #New York #Class Action #Levi & Korsinsky #Embecta Corp

Embecta Corp Faces Major Legal Challenges

On July 22, 2026, Levi & Korsinsky, LLP announced a significant legal development involving Embecta Corp. (NASDAQ: EMBC). The announcement was aimed at investors affected by the company's recent dramatic drop in stock value. The firm is spearheading a securities class action lawsuit against Embecta, specifically naming two of its senior executives: Devdatt Kurdikar, the CEO, and Jacob P. Elguicze, the CFO.

Context of the Lawsuit

This class action has emerged amidst grave accusations that the leadership at Embecta misrepresented the fiscal health of the company, particularly during a crucial period spanning from November 25, 2025, to May 4, 2026. During this time, the company’s shares plummeted an alarming 57.8%, translating to a loss of $5.35 per share, which left many investors reeling. This dramatic decline occurred after the company disclosed that its U.S. operations had deteriorated significantly more than what was earlier suggested during financial reports and calls.

Details of the Allegations

The central allegation in this lawsuit is that Kurdikar and Elguicze certified misleading guidance while allegedly being aware of adverse company information. Specifically, they are accused of reaffirming a revenue guidance range of $1.071 billion to $1.093 billion during their Q1 earnings call despite knowing that the pen needle market in the U.S. was suffering. During the J.P. Morgan Healthcare Conference in January 2026, Kurdikar described the pen needle business as “incredibly resolute,” maintaining an image of stability even amidst deteriorating conditions.

The court documents claim that both executives had access to non-public information concerning the company's financial woes. This information of a competitive share loss at a major customer and unstable purchasing behaviors by patients represented a significant risk which the executives should have disclosed to avoid misleading the investing public.

Legal Framework

The lawsuit is built on claims stemming from Section 20(a) of the Securities Exchange Act, which holds individuals liable if they are in control of the entity that commits a primary violation of the securities laws. It argues that as controlling persons, both Kurdikar and Elguicze had the ability to correct misleading statements or prevent them from being issued—a responsibility they allegedly failed to uphold.

Moreover, the complaint emphasizes the Sarbanes-Oxley Act’s certification standards, which require top executives to personally affirm that the company’s financial filings accurately reflect its financial condition. The executives are also accused of disregarding material changes in internal controls that could have affected investors' decision-making. The standard of scienter, or intent to deceive, is also a critical aspect of this lawsuit as it claims both individuals consciously chose not to disclose adverse operational conditions.

Actions for Affected Investors

The court has set August 17, 2026, as the deadline for affected investors to apply for lead plaintiff status, which raises critical considerations for those who believe their financial interests may have been compromised. Investors are encouraged to gather records of their Embecta stock purchases, including dates and quantities, to assess their potential for recovering losses. Interested individuals can contact Levi & Korsinsky for a preliminary evaluation without any immediate obligation.

Joseph E. Levi, an attorney at Levi & Korsinsky, asserts that corporate officers have a stringent responsibility to ensure their public statements are accurate. Should they fail to uphold this duty while certifying financial guidance, the law provides an avenue for shareholders to take recourse against them.

The implications of this class action signify a pressing reminder of the accountability that corporate leaders must bear for their public assertions, particularly in the dynamic sector of healthcare technology. As events unfold, it remains crucial for shareholders to stay informed and engaged in the progression of this significant legal battle that seeks to hold corporate governance accountable.

For further inquiries and to explore options, affected investors can reach out directly to Levi & Korsinsky at their New York office, or visit their website for more information on how to proceed with potential claims.